Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling-Reference-Cited by-同舟云学术

Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling

Published:2023-01-08 Issue:3 Volume:12 Page:320-332
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Yeung Cindy H. T.¹^ORCID,Beers Jessica L.²^ORCID,Jackson Klarissa D.²,Edginton Andrea N.¹

Affiliation:

1. School of Pharmacy University of Waterloo Waterloo Ontario Canada

2. Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill California USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12908

Reference52 articles.

1. Phytocannabinoids: a unified critical inventory

2. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

3. Center for Drug Evaluation and Research.Clinical Pharmacology and Biopharmaceutics Review(s): Epidiolex.2017. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf. [Accessed March 31 2022].

4. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis;Cannabis and Cannabinoid Research;2024-04-16

2. CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions;Pharmaceutics;2024-04-01

3. Oral delivery of cannabidiol: Revealing the formulation and absorption challenges;Journal of Drug Delivery Science and Technology;2024-02

4. Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity;Drug Metabolism and Disposition;2024-01-29

5. Drug interactions of tetrahydrocannabinol and cannabidiol in cannabinoid drugs;Deutsches Ärzteblatt international;2023-12-08